Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 24, 2016
ISSUE 25 - June 24, 2016 PDF



Stanford, Intermountain and Providence Use Syapse Platform to Integrate Their Data

Three health systems—Stanford Cancer Institute, Intermountain Healthcare and Providence Health and Services—have agreed to eliminate the electronic barriers between their medical records, tumor registries and genomics databases.

The three entities said they have started to use a common IT platform to achieve interoperability and guide clinical decision-making.

That platform is Syapse, a startup that is emerging as an important player in the ongoing conversation on bioinformatics and data sharing in oncology, led by Vice President Joe Biden and the National Cancer Moonshot Initiative.

• Related Coverage of the Cancer Moonshot

Conversation with The Cancer Letter

Hirsch: I Dropped Out of Stanford to Start Syapse

Jonathan Hirsch was studying neuroscience at Stanford University when he wandered into two oncology classes and saw an opportunity to change the way health systems handle genomic data.

“I started getting really immersed in molecular oncology, and the challenges in implementing molecularly guided treatment started coming together with the challenges in utilizing complex data,” Hirsch said to The Cancer Letter.

Joint BSA-NCAB Meeting

The Moonshot’s Metric for Success: Avoiding a Single, Tangible Endpoint

How will the success of the moonshot be measured? NCI Acting Director Doug Lowy touched on the subject during the joint meeting of the institute’s Board of Scientific Advisors and the National Cancer Advisory Board June 21.

The moonshots of the 1960s were essentially engineering problems that had tangible goals. Cancer is an evolutionary problem, and the stated goal of the moonshot in cancer research, led by Vice President Joe Biden, is perhaps deliberately vague: to achieve a decade’s worth of progress in just five years.

“Has there been any discussion of an endpoint that you can point to—like planting the flag on the moon, or sequencing the three-billionth base pair of the genome project?” asked BSA member Lincoln Stein, director of the Informatics and BioComputing Platform at the Ontario Institute for Cancer Research, during the meeting. “Something that looks like an achievable endpoint?”

Funding Opportunity

SU2C, Merck Taking Proposals for Keytruda

Stand Up To Cancer announced a request for proposals under SU2C Catalyst, a program supporting clinical trials and translational research.

In Brief
  • NCI Surgery Branch resumes enrollment in immunotherapy trials
  • Rajesh Garg named president and CEO of Cancer Treatment Centers of America

  • Prostate Cancer Foundation names 24 Young Investigator Award winners

  • Shuanzeng "Sam" Wei and Phillip Pancari join Fox Chase

  • MIT's Tyler Jacks, Susan Hockfield, and Phillip Sharp publish report on convergence

  • Pancreatic Cancer Action Network lobbies Congress for research funding

  • Leukemia and Lymphoma Society and the American Society of Hematology to collaborate on promoting AML treatment research

 


Copyright (c) 2016 The Cancer Letter Inc.

Letter